Cover Image
市場調查報告書

Herantis Pharma plc.的產品平台分析

Herantis Pharma Plc - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321997
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Herantis Pharma plc.的產品平台分析 Herantis Pharma Plc - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 28 Pages
簡介

Herantis Pharma plc.是總公司設立於芬蘭的生物製藥企業。專門開發針對未滿足醫療需求的新藥,開發對象囊括乾眼症,帕金森氏症,續發性淋巴水腫,異位性皮膚炎,肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)等多元化領域的治療藥。

本報告提供Herantis Pharma plc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Herantis Pharma plc.的基本資料

  • Herantis Pharma plc.概要
  • 主要資訊
  • 企業資料

Herantis Pharma plc.:R&D概要

  • 主要的治療範圍

Herantis Pharma plc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Herantis Pharma plc.:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Herantis Pharma plc.:藥物簡介

  • Small Molecule for Immunology, Ophthalmology, Oncology and Dermatology
  • HER-902
  • LX-1101
  • Recombinant Protein for Amyotrophic Lateral Sclerosis

Herantis Pharma plc.:開發平台分析

  • 標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Herantis Pharma plc.:最新的開發平台資訊

Herantis Pharma plc.:開發暫停中的計劃

Herantis Pharma plc.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07725CDB

Summary

Global Markets Direct's, 'Herantis Pharma Plc - Product Pipeline Review - 2015', provides an overview of the Herantis Pharma Plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Herantis Pharma Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Herantis Pharma Plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Herantis Pharma Plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Herantis Pharma Plc's pipeline products

Reasons to buy

  • Evaluate Herantis Pharma Plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Herantis Pharma Plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Herantis Pharma Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Herantis Pharma Plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Herantis Pharma Plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Herantis Pharma Plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Herantis Pharma Plc Snapshot
    • Herantis Pharma Plc Overview
    • Key Information
    • Key Facts
  • Herantis Pharma Plc - Research and Development Overview
    • Key Therapeutic Areas
  • Herantis Pharma Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Herantis Pharma Plc - Pipeline Products Glance
    • Herantis Pharma Plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Herantis Pharma Plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Herantis Pharma Plc - Drug Profiles
    • Cis-Urocanic Acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HER-902
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-1101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protien for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protien for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Herantis Pharma Plc - Pipeline Analysis
    • Herantis Pharma Plc - Pipeline Products by Target
    • Herantis Pharma Plc - Pipeline Products by Route of Administration
    • Herantis Pharma Plc - Pipeline Products by Molecule Type
    • Herantis Pharma Plc - Pipeline Products by Mechanism of Action
  • Herantis Pharma Plc - Recent Pipeline Updates
  • Herantis Pharma Plc - Dormant Projects
  • Herantis Pharma Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Herantis Pharma Plc, Key Information
  • Herantis Pharma Plc, Key Facts
  • Herantis Pharma Plc - Pipeline by Indication, 2015
  • Herantis Pharma Plc - Pipeline by Stage of Development, 2015
  • Herantis Pharma Plc - Monotherapy Products in Pipeline, 2015
  • Herantis Pharma Plc - Phase II, 2015
  • Herantis Pharma Plc - Preclinical, 2015
  • Herantis Pharma Plc - Pipeline by Target, 2015
  • Herantis Pharma Plc - Pipeline by Route of Administration, 2015
  • Herantis Pharma Plc - Pipeline by Molecule Type, 2015
  • Herantis Pharma Plc - Pipeline Products by Mechanism of Action, 2015
  • Herantis Pharma Plc - Recent Pipeline Updates, 2015
  • Herantis Pharma Plc - Dormant Developmental Projects,2015
  • Herantis Pharma Plc, Other Locations

List of Figures

  • Herantis Pharma Plc - Pipeline by Top 10 Indication, 2015
  • Herantis Pharma Plc - Pipeline by Stage of Development, 2015
  • Herantis Pharma Plc - Monotherapy Products in Pipeline, 2015
  • Herantis Pharma Plc - Pipeline by Top 10 Route of Administration, 2015
  • Herantis Pharma Plc - Pipeline by Top 10 Molecule Type, 2015
Back to Top